Race Oncology (ASX:RAC) has received human ethics approval to commence its HARNESS-1 Phase 1a/b clinical trial evaluating RC220, its next-generation formulation of bisantrene, in combination with AstraZeneca's TAGRISSO (osimertinib) for patients with EGFR-mutated non-small cell lung cancer. …
Race Oncology secures human ethics approval for lung cancer trial of RC220
November 26, 2025 Australian Biotech
Latest Video
New Stories
-
Slade Pharmacy marks anniversary with record research contributions at conferences
November 26, 2025 - - Latest News -
US Medicare sets reimbursement price for PromarkerD, paving way for major commercial rollout
November 26, 2025 - - Australian Biotech -
Recce reports strong preclinical efficacy for inhaled R327 in hospital-acquired pneumonia model
November 26, 2025 - - Australian Biotech -
Race Oncology secures human ethics approval for lung cancer trial of RC220
November 26, 2025 - - Australian Biotech -
Syntara advances next-generation anti-fibrotic cream into Phase 1b trial
November 26, 2025 - - Australian Biotech -
AdAlta chair says the company is 'on the cusp' of transformational growth
November 26, 2025 - - Australian Biotech -
Scorecard reveals Australia is still ignoring its deadliest and most costly cancer
November 26, 2025 - - Latest News